Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Understanding the small print: a 5-year review of readability in phase I trial information leaflets.

Trials·2026

Same author

Detection of airborne bovine coronavirus RNA in pen environments and exhaled breath of calves.

JDS communications·2026

Same author

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.

Clinical pharmacology and therapeutics·2026

Same author

Surface sampling pre- and post-decontamination in UK hospital rooms occupied by a 2021 household cluster of clade IIb mpox cases.

The Journal of hospital infection·2026

Same author

Persistent physical symptoms not explained by structural abnormalities or disease processes: a primary care approach to promote recovery.

Scandinavian journal of primary health care·2026

Same author

Multiplex PCR to Differentiate Monkeypox Virus Clades.

Emerging infectious diseases·2026

Search research articles

Related Experiment Video

Updated: Aug 7, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Therapeutics for treating mpox in humans.

Tilly Fox¹, Susan Gould², Naveena Princy³

¹Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.

The Cochrane Database of Systematic Reviews

|March 14, 2023

Summary

This summary is machine-generated.

No randomized controlled trials (RCTs) were found for mpox therapeutics. Non-randomized studies suggest tecovirimat is safe, but brincidofovir may cause liver injury, requiring further investigation.

More Related Videos

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

Related Experiment Videos

Last Updated: Aug 7, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

Area of Science:

Virology
Infectious Diseases
Public Health

Background:

Mpox (monkeypox) declared a Public Health Emergency of International Concern (PHEIC) by WHO in July 2022.
No licensed therapeutics currently exist for mpox treatment.
Efficacy and safety of potential mpox treatments require rigorous investigation.

Approach:

Systematic review of randomized controlled trials (RCTs) for mpox therapeutic effectiveness.
Narrative review of non-randomized studies (NRS) for mpox therapeutic safety.
Comprehensive database searches and expert consultation for study identification.

Key Points:

No completed RCTs were identified for mpox therapeutic effectiveness.
Five ongoing RCTs are evaluating tecovirimat for mpox treatment.
NRS indicate tecovirimat has no serious safety signals; brincidofovir shows a possible liver injury signal.

Conclusions:

Currently, no RCT evidence exists for mpox therapeutic efficacy or safety in humans.
Tecovirimat appears safe based on limited NRS data.
Brincidofovir warrants further monitoring for potential liver injury in mpox patients.